LGA
ABBV icon

Lebenthal Global Advisors’s AbbVie ABBV Stock Holding History

Lebenthal Global Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-200
Closed -$45.7K – 193
2025
Q4 		$45.7K Buy
+200
New +$45.6K 0.01% 182

Other funds holding ABBV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Lebenthal Global Advisors's ABBV Position: Q2 2026 in Review

Lebenthal Global Advisors reduced its AbbVie (ABBV) stake by 5.7% in Q2 2026, selling an estimated $46.3K and leaving 3,529 shares worth $888K. The position accounts for 0.12% of the portfolio, ranked #127.

Lebenthal Global Advisors first reported a position in ABBV in Q4 2020 and has held it in 23 quarters since. The position peaked at $1.25M in Q1 2022. 4,234 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Lebenthal Global Advisors held 3,529 shares of AbbVie worth $888K as of Q2 2026.
  • Lebenthal Global Advisors sold 215 AbbVie shares in Q2 2026, an estimated $46.3K.
  • AbbVie made up 0.12% of Lebenthal Global Advisors's portfolio in Q2 2026, its #127 holding.
  • Lebenthal Global Advisors first reported a position in AbbVie in Q4 2020 and has held it in 23 quarters since.
  • Lebenthal Global Advisors's AbbVie position peaked at $1.25M in Q1 2022.
  • 4,234 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Lebenthal Global Advisors's 13F filing for Q2 2026, filed 30 Jul 2026.